Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-c-MET monoclonal antibody HLX55

A humanized immunoglobulin (Ig) G2 monoclonal antibody directed against the human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Upon administration, anti-c-Met monoclonal antibody HLX55 specifically binds to the semaphorin (Sema)/Plexins-Semaphorins-Integrins (PSI) domain of c-Met, which prevents the binding of c-Met to its ligand HGF and the subsequent activation of the HGF/c-Met signaling pathway. In addition, HLX55 promotes c-Met degradation, which further inhibits c-Met-mediated signaling. This may result in cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:HLX 55
HLX-55
HLX55
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search